Literature DB >> 12738992

Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.

Andrea Hessenauer1, Mathias Montenarh, Claudia Götz.   

Abstract

Protein kinase CK2 seems to play an essential role in cellular growth regulation as well as in apoptosis. By using a pair of prostate carcinoma cell lines which are either hormone-sensitive (LNCaP cells) or hormone-refractory (PC-3 cells) we analysed the contribution of protein kinase CK2 to their different growth behaviour as well as to apoptosis. We found the same amount of CK2 subunits in both cell lines although the enzymatic activity of CK2 was much higher in the hormone-refractory cells. These results for the first time show a correlation between the specific activity of protein kinase CK2 and specific growth properties of prostate cancer cells. The antiproliferative flavonoid apigenin led to an inhibition of the CK2 activity in both types of cells but only the hormone-sensitive LNCaP cells responded with apoptosis. Thus, these results demonstrate that a high CK2 activity is dispensable for growth and not necessary for a protection against apoptosis in hormone-refractory prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738992

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines.

Authors:  Carolin C Schneider; Claudia Götz; Andrea Hessenauer; Jürgen Günther; Sabine Kartarius; Mathias Montenarh
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

Review 2.  NF-kappaB in carcinoma therapy and prevention.

Authors:  Matthew Brown; Jonah Cohen; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Expert Opin Ther Targets       Date:  2008-09       Impact factor: 6.902

3.  Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA.

Authors:  Xing Liu; Vincent H Tam; Ming Hu
Journal:  Mol Pharm       Date:  2007-10-10       Impact factor: 4.939

Review 4.  Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention.

Authors:  Xin Tong; Jill C Pelling
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

5.  Immunologically defined subclasses of the protein kinase CK2 beta-subunit in prostate carcinoma cell lines.

Authors:  Claudia Götz; Sabine Kartarius; Sarah Schetting; Mathias Montenarh
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

6.  CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.

Authors:  Chuangzhong Deng; Jieping Chen; Shengjie Guo; Yanjun Wang; Qianghua Zhou; Zaishang Li; Xingping Yang; Xingsu Yu; Zhenfeng Zhang; Fangjian Zhou; Hui Han; Kai Yao
Journal:  World J Urol       Date:  2017-01-19       Impact factor: 4.226

7.  Plant flavone apigenin: An emerging anticancer agent.

Authors:  Eswar Shankar; Aditi Goel; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

Review 8.  [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Authors:  L Rinnab; A Hessenauer; S V Schütz; E Schmid; R Küfer; F Finter; R E Hautmann; K D Spindler; M V Cronauer
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

9.  Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Authors:  Wei Luo; Wei-Dong Yu; Yingyu Ma; Mikhail Chernov; Donald L Trump; Candace S Johnson
Journal:  Cancer Res       Date:  2013-01-28       Impact factor: 12.701

10.  Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.

Authors:  A A Kramerov; M Saghizadeh; S Caballero; L C Shaw; S Li Calzi; M Bretner; M Montenarh; L A Pinna; M B Grant; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.